

Global Dual GLP-1R/GIPR Receptor Agonist Market Growth 2026-2032

<https://marketpublishers.com/r/GE56925F1292EN.html>

Date: May 2026

Pages: 94

Price: US\$ 3,660.00 (Single User License)

ID: GE56925F1292EN

Abstracts

The global Dual GLP-1R/GIPR Receptor Agonist market size is predicted to grow from US\$ 29966 million in 2025 to US\$ 64976 million in 2032; it is expected to grow at a CAGR of 11.6% from 2026 to 2032.

In 2025, global Dual GLP-1R/GIPR Receptor Agonist production reached approximately 161.44 M Units, with an average global market price of around 189.74 USD per Unit.

A Dual GLP-1R/GIPR Receptor Agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity. To date, Tirzepatide is the only commercially available Dual GLP-1R/GIPR Receptor Agonist product in the world.

Dual GLP-1R/GIPR Receptor Agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven

by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma's most strategically important therapeutic area.

The upstream raw materials for Dual GLP-1R/GIPR Receptor Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.

The single-line production capacity of Dual GLP-1R/GIPR Receptor Agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.

United States market for Dual GLP-1R/GIPR Receptor Agonist is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Dual GLP-1R/GIPR Receptor Agonist is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Dual GLP-1R/GIPR Receptor Agonist is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Dual GLP-1R/GIPR Receptor Agonist players cover Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the "Dual GLP-1R/GIPR Receptor Agonist Industry Forecast" looks at past sales and reviews total world Dual GLP-1R/GIPR Receptor Agonist sales in 2025, providing a comprehensive analysis by region and market sector of projected Dual GLP-1R/GIPR Receptor Agonist sales for 2026 through 2032. With Dual GLP-1R/GIPR Receptor Agonist sales broken down by

region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Dual GLP-1R/GIPR Receptor Agonist industry.

This Insight Report provides a comprehensive analysis of the global Dual GLP-1R/GIPR Receptor Agonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dual GLP-1R/GIPR Receptor Agonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Dual GLP-1R/GIPR Receptor Agonist market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dual GLP-1R/GIPR Receptor Agonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dual GLP-1R/GIPR Receptor Agonist.

This report presents a comprehensive overview, market shares, and growth opportunities of Dual GLP-1R/GIPR Receptor Agonist market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Injection

Oral Administration

Segmentation by Receptor Agonist Properties:

Balanced

Biased

Segmentation by Medicinal Efficacy:

Long-acting

Short-acting

Segmentation by Application:

Diabetes

Obesity

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Eli Lilly

Roche

Viking Therapeutics

Asclepis Pharma

Jiangsu Hengrui Medicine

East China Pharmaceutical

Tonghua Dongbao Pharmaceutical

Lepu Medical Technology

Hansoh Pharma

Key Questions Addressed in this Report

What is the 10-year outlook for the global Dual GLP-1R/GIPR Receptor Agonist market?

What factors are driving Dual GLP-1R/GIPR Receptor Agonist market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Dual GLP-1R/GIPR Receptor Agonist market opportunities vary by end market size?

How does Dual GLP-1R/GIPR Receptor Agonist break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Dual GLP-1R/GIPR Receptor Agonist Annual Sales 2021-2032

2.1.2 World Current & Future Analysis for Dual GLP-1R/GIPR Receptor Agonist by Geographic Region, 2021, 2025 & 2032

2.1.3 World Current & Future Analysis for Dual GLP-1R/GIPR Receptor Agonist by Country/Region, 2021, 2025 & 2032

2.2 Dual GLP-1R/GIPR Receptor Agonist Segment by Type

2.2.1 Injection

2.2.2 Oral Administration

2.2.3 Dual GLP-1R/GIPR Receptor Agonist Sales by Type

2.2.3.1 Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Type (2021-2026)

2.2.3.2 Global Dual GLP-1R/GIPR Receptor Agonist Revenue and Market Share by Type (2021-2026)

2.2.3.3 Global Dual GLP-1R/GIPR Receptor Agonist Sale Price by Type (2021-2026)

2.3 Dual GLP-1R/GIPR Receptor Agonist Segment by Receptor Agonist Properties

2.3.1 Balanced

2.3.2 Biased

2.3.3 Dual GLP-1R/GIPR Receptor Agonist Sales by Receptor Agonist Properties

2.3.3.1 Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Receptor Agonist Properties (2021-2026)

2.3.3.2 Global Dual GLP-1R/GIPR Receptor Agonist Revenue and Market Share by Receptor Agonist Properties (2021-2026)

2.3.3.3 Global Dual GLP-1R/GIPR Receptor Agonist Sale Price by Receptor Agonist

Properties (2021-2026)

2.4 Dual GLP-1R/GIPR Receptor Agonist Segment by Medicinal Efficacy

2.4.1 Long-acting

2.4.2 Short-acting

2.4.3 Dual GLP-1R/GIPR Receptor Agonist Sales by Medicinal Efficacy

2.4.3.1 Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Medicinal Efficacy (2021-2026)

2.4.3.2 Global Dual GLP-1R/GIPR Receptor Agonist Revenue and Market Share by Medicinal Efficacy (2021-2026)

2.4.3.3 Global Dual GLP-1R/GIPR Receptor Agonist Sale Price by Medicinal Efficacy (2021-2026)

2.5 Dual GLP-1R/GIPR Receptor Agonist Segment by Application

2.5.1 Diabetes

2.5.2 Obesity

2.5.3 Others

2.5.4 Dual GLP-1R/GIPR Receptor Agonist Sales by Application

2.5.4.1 Global Dual GLP-1R/GIPR Receptor Agonist Sale Market Share by Application (2021-2026)

2.5.4.2 Global Dual GLP-1R/GIPR Receptor Agonist Revenue and Market Share by Application (2021-2026)

2.5.4.3 Global Dual GLP-1R/GIPR Receptor Agonist Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Dual GLP-1R/GIPR Receptor Agonist Breakdown Data by Company

3.1.1 Global Dual GLP-1R/GIPR Receptor Agonist Annual Sales by Company (2021-2026)

3.1.2 Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Company (2021-2026)

3.2 Global Dual GLP-1R/GIPR Receptor Agonist Annual Revenue by Company (2021-2026)

3.2.1 Global Dual GLP-1R/GIPR Receptor Agonist Revenue by Company (2021-2026)

3.2.2 Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Company (2021-2026)

3.3 Global Dual GLP-1R/GIPR Receptor Agonist Sale Price by Company

3.4 Key Manufacturers Dual GLP-1R/GIPR Receptor Agonist Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Dual GLP-1R/GIPR Receptor Agonist Product Location

Distribution

3.4.2 Players Dual GLP-1R/GIPR Receptor Agonist Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR DUAL GLP-1R/GIPR RECEPTOR AGONIST BY GEOGRAPHIC REGION

4.1 World Historic Dual GLP-1R/GIPR Receptor Agonist Market Size by Geographic Region (2021-2026)

4.1.1 Global Dual GLP-1R/GIPR Receptor Agonist Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Dual GLP-1R/GIPR Receptor Agonist Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Dual GLP-1R/GIPR Receptor Agonist Market Size by Country/Region (2021-2026)

4.2.1 Global Dual GLP-1R/GIPR Receptor Agonist Annual Sales by Country/Region (2021-2026)

4.2.2 Global Dual GLP-1R/GIPR Receptor Agonist Annual Revenue by Country/Region (2021-2026)

4.3 Americas Dual GLP-1R/GIPR Receptor Agonist Sales Growth

4.4 APAC Dual GLP-1R/GIPR Receptor Agonist Sales Growth

4.5 Europe Dual GLP-1R/GIPR Receptor Agonist Sales Growth

4.6 Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Growth

5 AMERICAS

5.1 Americas Dual GLP-1R/GIPR Receptor Agonist Sales by Country

5.1.1 Americas Dual GLP-1R/GIPR Receptor Agonist Sales by Country (2021-2026)

5.1.2 Americas Dual GLP-1R/GIPR Receptor Agonist Revenue by Country (2021-2026)

5.2 Americas Dual GLP-1R/GIPR Receptor Agonist Sales by Type (2021-2026)

5.3 Americas Dual GLP-1R/GIPR Receptor Agonist Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Dual GLP-1R/GIPR Receptor Agonist Sales by Region

6.1.1 APAC Dual GLP-1R/GIPR Receptor Agonist Sales by Region (2021-2026)

6.1.2 APAC Dual GLP-1R/GIPR Receptor Agonist Revenue by Region (2021-2026)

6.2 APAC Dual GLP-1R/GIPR Receptor Agonist Sales by Type (2021-2026)

6.3 APAC Dual GLP-1R/GIPR Receptor Agonist Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Dual GLP-1R/GIPR Receptor Agonist by Country

7.1.1 Europe Dual GLP-1R/GIPR Receptor Agonist Sales by Country (2021-2026)

7.1.2 Europe Dual GLP-1R/GIPR Receptor Agonist Revenue by Country (2021-2026)

7.2 Europe Dual GLP-1R/GIPR Receptor Agonist Sales by Type (2021-2026)

7.3 Europe Dual GLP-1R/GIPR Receptor Agonist Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist by Country

8.1.1 Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales by Country (2021-2026)

8.1.2 Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Revenue by Country (2021-2026)

8.2 Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales by Type (2021-2026)

8.3 Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Dual GLP-1R/GIPR Receptor Agonist

10.3 Manufacturing Process Analysis of Dual GLP-1R/GIPR Receptor Agonist

10.4 Industry Chain Structure of Dual GLP-1R/GIPR Receptor Agonist

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Dual GLP-1R/GIPR Receptor Agonist Distributors

11.3 Dual GLP-1R/GIPR Receptor Agonist Customer

12 WORLD FORECAST REVIEW FOR DUAL GLP-1R/GIPR RECEPTOR AGONIST BY GEOGRAPHIC REGION

12.1 Global Dual GLP-1R/GIPR Receptor Agonist Market Size Forecast by Region

12.1.1 Global Dual GLP-1R/GIPR Receptor Agonist Forecast by Region (2027-2032)

12.1.2 Global Dual GLP-1R/GIPR Receptor Agonist Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Dual GLP-1R/GIPR Receptor Agonist Forecast by Type (2027-2032)

12.7 Global Dual GLP-1R/GIPR Receptor Agonist Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Eli Lilly

13.1.1 Eli Lilly Company Information

13.1.2 Eli Lilly Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications

13.1.3 Eli Lilly Dual GLP-1R/GIPR Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Eli Lilly Main Business Overview

13.1.5 Eli Lilly Latest Developments

13.2 Roche

13.2.1 Roche Company Information

13.2.2 Roche Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications

13.2.3 Roche Dual GLP-1R/GIPR Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Roche Main Business Overview

13.2.5 Roche Latest Developments

13.3 Viking Therapeutics

13.3.1 Viking Therapeutics Company Information

13.3.2 Viking Therapeutics Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications

13.3.3 Viking Therapeutics Dual GLP-1R/GIPR Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Viking Therapeutics Main Business Overview

13.3.5 Viking Therapeutics Latest Developments

13.4 Ascletois Pharma

13.4.1 Ascletois Pharma Company Information

13.4.2 Ascletois Pharma Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications

13.4.3 Ascletois Pharma Dual GLP-1R/GIPR Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Ascletois Pharma Main Business Overview

13.4.5 Ascletois Pharma Latest Developments

13.5 Jiangsu Hengrui Medicine

- 13.5.1 Jiangsu Hengrui Medicine Company Information
- 13.5.2 Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications
- 13.5.3 Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.5.4 Jiangsu Hengrui Medicine Main Business Overview
- 13.5.5 Jiangsu Hengrui Medicine Latest Developments
- 13.6 East China Pharmaceutical
 - 13.6.1 East China Pharmaceutical Company Information
 - 13.6.2 East China Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications
 - 13.6.3 East China Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 East China Pharmaceutical Main Business Overview
 - 13.6.5 East China Pharmaceutical Latest Developments
- 13.7 Tonghua Dongbao Pharmaceutical
 - 13.7.1 Tonghua Dongbao Pharmaceutical Company Information
 - 13.7.2 Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications
 - 13.7.3 Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.7.4 Tonghua Dongbao Pharmaceutical Main Business Overview
 - 13.7.5 Tonghua Dongbao Pharmaceutical Latest Developments
- 13.8 Lepu Medical Technology
 - 13.8.1 Lepu Medical Technology Company Information
 - 13.8.2 Lepu Medical Technology Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications
 - 13.8.3 Lepu Medical Technology Dual GLP-1R/GIPR Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.8.4 Lepu Medical Technology Main Business Overview
 - 13.8.5 Lepu Medical Technology Latest Developments
- 13.9 Hansoh Pharma
 - 13.9.1 Hansoh Pharma Company Information
 - 13.9.2 Hansoh Pharma Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications
 - 13.9.3 Hansoh Pharma Dual GLP-1R/GIPR Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.9.4 Hansoh Pharma Main Business Overview
 - 13.9.5 Hansoh Pharma Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Dual GLP-1R/GIPR Receptor Agonist Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Dual GLP-1R/GIPR Receptor Agonist Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Injection

Table 4. Major Players of Oral Administration

Table 5. Global Dual GLP-1R/GIPR Receptor Agonist Sales by Type (2021-2026) & (K Units)

Table 6. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Type (2021-2026)

Table 7. Global Dual GLP-1R/GIPR Receptor Agonist Revenue by Type (2021-2026) & (\$ million)

Table 8. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Type (2021-2026)

Table 9. Global Dual GLP-1R/GIPR Receptor Agonist Sale Price by Type (2021-2026) & (US\$/Unit)

Table 10. Major Players of Balanced

Table 11. Major Players of Biased

Table 12. Global Dual GLP-1R/GIPR Receptor Agonist Sales by Receptor Agonist Properties (2021-2026) & (K Units)

Table 13. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Receptor Agonist Properties (2021-2026)

Table 14. Global Dual GLP-1R/GIPR Receptor Agonist Revenue by Receptor Agonist Properties (2021-2026) & (\$ million)

Table 15. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Receptor Agonist Properties (2021-2026)

Table 16. Global Dual GLP-1R/GIPR Receptor Agonist Sale Price by Receptor Agonist Properties (2021-2026) & (US\$/Unit)

Table 17. Major Players of Long-acting

Table 18. Major Players of Short-acting

Table 19. Global Dual GLP-1R/GIPR Receptor Agonist Sales by Medicinal Efficacy (2021-2026) & (K Units)

Table 20. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Medicinal Efficacy (2021-2026)

Table 21. Global Dual GLP-1R/GIPR Receptor Agonist Revenue by Medicinal Efficacy

(2021-2026) & (\$ million)

Table 22. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Medicinal Efficacy (2021-2026)

Table 23. Global Dual GLP-1R/GIPR Receptor Agonist Sale Price by Medicinal Efficacy (2021-2026) & (US\$/Unit)

Table 24. Global Dual GLP-1R/GIPR Receptor Agonist Sale by Application (2021-2026) & (K Units)

Table 25. Global Dual GLP-1R/GIPR Receptor Agonist Sale Market Share by Application (2021-2026)

Table 26. Global Dual GLP-1R/GIPR Receptor Agonist Revenue by Application (2021-2026) & (\$ million)

Table 27. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Application (2021-2026)

Table 28. Global Dual GLP-1R/GIPR Receptor Agonist Sale Price by Application (2021-2026) & (US\$/Unit)

Table 29. Global Dual GLP-1R/GIPR Receptor Agonist Sales by Company (2021-2026) & (K Units)

Table 30. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Company (2021-2026)

Table 31. Global Dual GLP-1R/GIPR Receptor Agonist Revenue by Company (2021-2026) & (\$ millions)

Table 32. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Company (2021-2026)

Table 33. Global Dual GLP-1R/GIPR Receptor Agonist Sale Price by Company (2021-2026) & (US\$/Unit)

Table 34. Key Manufacturers Dual GLP-1R/GIPR Receptor Agonist Producing Area Distribution and Sales Area

Table 35. Players Dual GLP-1R/GIPR Receptor Agonist Products Offered

Table 36. Dual GLP-1R/GIPR Receptor Agonist Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 37. New Products and Potential Entrants

Table 38. Market M&A Activity & Strategy

Table 39. Global Dual GLP-1R/GIPR Receptor Agonist Sales by Geographic Region (2021-2026) & (K Units)

Table 40. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share Geographic Region (2021-2026)

Table 41. Global Dual GLP-1R/GIPR Receptor Agonist Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 42. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by

Geographic Region (2021-2026)

Table 43. Global Dual GLP-1R/GIPR Receptor Agonist Sales by Country/Region (2021-2026) & (K Units)

Table 44. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Country/Region (2021-2026)

Table 45. Global Dual GLP-1R/GIPR Receptor Agonist Revenue by Country/Region (2021-2026) & (\$ millions)

Table 46. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Country/Region (2021-2026)

Table 47. Americas Dual GLP-1R/GIPR Receptor Agonist Sales by Country (2021-2026) & (K Units)

Table 48. Americas Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Country (2021-2026)

Table 49. Americas Dual GLP-1R/GIPR Receptor Agonist Revenue by Country (2021-2026) & (\$ millions)

Table 50. Americas Dual GLP-1R/GIPR Receptor Agonist Sales by Type (2021-2026) & (K Units)

Table 51. Americas Dual GLP-1R/GIPR Receptor Agonist Sales by Application (2021-2026) & (K Units)

Table 52. APAC Dual GLP-1R/GIPR Receptor Agonist Sales by Region (2021-2026) & (K Units)

Table 53. APAC Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Region (2021-2026)

Table 54. APAC Dual GLP-1R/GIPR Receptor Agonist Revenue by Region (2021-2026) & (\$ millions)

Table 55. APAC Dual GLP-1R/GIPR Receptor Agonist Sales by Type (2021-2026) & (K Units)

Table 56. APAC Dual GLP-1R/GIPR Receptor Agonist Sales by Application (2021-2026) & (K Units)

Table 57. Europe Dual GLP-1R/GIPR Receptor Agonist Sales by Country (2021-2026) & (K Units)

Table 58. Europe Dual GLP-1R/GIPR Receptor Agonist Revenue by Country (2021-2026) & (\$ millions)

Table 59. Europe Dual GLP-1R/GIPR Receptor Agonist Sales by Type (2021-2026) & (K Units)

Table 60. Europe Dual GLP-1R/GIPR Receptor Agonist Sales by Application (2021-2026) & (K Units)

Table 61. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales by Country (2021-2026) & (K Units)

Table 62. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Country (2021-2026)

Table 63. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales by Type (2021-2026) & (K Units)

Table 64. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales by Application (2021-2026) & (K Units)

Table 65. Key Market Drivers & Growth Opportunities of Dual GLP-1R/GIPR Receptor Agonist

Table 66. Key Market Challenges & Risks of Dual GLP-1R/GIPR Receptor Agonist

Table 67. Key Industry Trends of Dual GLP-1R/GIPR Receptor Agonist

Table 68. Dual GLP-1R/GIPR Receptor Agonist Raw Material

Table 69. Key Suppliers of Raw Materials

Table 70. Dual GLP-1R/GIPR Receptor Agonist Distributors List

Table 71. Dual GLP-1R/GIPR Receptor Agonist Customer List

Table 72. Global Dual GLP-1R/GIPR Receptor Agonist Sales Forecast by Region (2027-2032) & (K Units)

Table 73. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 74. Americas Dual GLP-1R/GIPR Receptor Agonist Sales Forecast by Country (2027-2032) & (K Units)

Table 75. Americas Dual GLP-1R/GIPR Receptor Agonist Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 76. APAC Dual GLP-1R/GIPR Receptor Agonist Sales Forecast by Region (2027-2032) & (K Units)

Table 77. APAC Dual GLP-1R/GIPR Receptor Agonist Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 78. Europe Dual GLP-1R/GIPR Receptor Agonist Sales Forecast by Country (2027-2032) & (K Units)

Table 79. Europe Dual GLP-1R/GIPR Receptor Agonist Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 80. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Forecast by Country (2027-2032) & (K Units)

Table 81. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 82. Global Dual GLP-1R/GIPR Receptor Agonist Sales Forecast by Type (2027-2032) & (K Units)

Table 83. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 84. Global Dual GLP-1R/GIPR Receptor Agonist Sales Forecast by Application

(2027-2032) & (K Units)

Table 85. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 86. Eli Lilly Basic Information, Dual GLP-1R/GIPR Receptor Agonist Manufacturing Base, Sales Area and Its Competitors

Table 87. Eli Lilly Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications

Table 88. Eli Lilly Dual GLP-1R/GIPR Receptor Agonist Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 89. Eli Lilly Main Business

Table 90. Eli Lilly Latest Developments

Table 91. Roche Basic Information, Dual GLP-1R/GIPR Receptor Agonist Manufacturing Base, Sales Area and Its Competitors

Table 92. Roche Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications

Table 93. Roche Dual GLP-1R/GIPR Receptor Agonist Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 94. Roche Main Business

Table 95. Roche Latest Developments

Table 96. Viking Therapeutics Basic Information, Dual GLP-1R/GIPR Receptor Agonist Manufacturing Base, Sales Area and Its Competitors

Table 97. Viking Therapeutics Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications

Table 98. Viking Therapeutics Dual GLP-1R/GIPR Receptor Agonist Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 99. Viking Therapeutics Main Business

Table 100. Viking Therapeutics Latest Developments

Table 101. Ascletis Pharma Basic Information, Dual GLP-1R/GIPR Receptor Agonist Manufacturing Base, Sales Area and Its Competitors

Table 102. Ascletis Pharma Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications

Table 103. Ascletis Pharma Dual GLP-1R/GIPR Receptor Agonist Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 104. Ascletis Pharma Main Business

Table 105. Ascletis Pharma Latest Developments

Table 106. Jiangsu Hengrui Medicine Basic Information, Dual GLP-1R/GIPR Receptor Agonist Manufacturing Base, Sales Area and Its Competitors

Table 107. Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications

Table 108. Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Receptor Agonist Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 109. Jiangsu Hengrui Medicine Main Business

Table 110. Jiangsu Hengrui Medicine Latest Developments

Table 111. East China Pharmaceutical Basic Information, Dual GLP-1R/GIPR Receptor Agonist Manufacturing Base, Sales Area and Its Competitors

Table 112. East China Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications

Table 113. East China Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 114. East China Pharmaceutical Main Business

Table 115. East China Pharmaceutical Latest Developments

Table 116. Tonghua Dongbao Pharmaceutical Basic Information, Dual GLP-1R/GIPR Receptor Agonist Manufacturing Base, Sales Area and Its Competitors

Table 117. Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications

Table 118. Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 119. Tonghua Dongbao Pharmaceutical Main Business

Table 120. Tonghua Dongbao Pharmaceutical Latest Developments

Table 121. Lepu Medical Technology Basic Information, Dual GLP-1R/GIPR Receptor Agonist Manufacturing Base, Sales Area and Its Competitors

Table 122. Lepu Medical Technology Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications

Table 123. Lepu Medical Technology Dual GLP-1R/GIPR Receptor Agonist Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 124. Lepu Medical Technology Main Business

Table 125. Lepu Medical Technology Latest Developments

Table 126. Hansoh Pharma Basic Information, Dual GLP-1R/GIPR Receptor Agonist Manufacturing Base, Sales Area and Its Competitors

Table 127. Hansoh Pharma Dual GLP-1R/GIPR Receptor Agonist Product Portfolios and Specifications

Table 128. Hansoh Pharma Dual GLP-1R/GIPR Receptor Agonist Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 129. Hansoh Pharma Main Business

Table 130. Hansoh Pharma Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Dual GLP-1R/GIPR Receptor Agonist
- Figure 2. Dual GLP-1R/GIPR Receptor Agonist Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Dual GLP-1R/GIPR Receptor Agonist Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Dual GLP-1R/GIPR Receptor Agonist Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Country/Region (2025)
- Figure 10. Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Injection
- Figure 12. Product Picture of Oral Administration
- Figure 13. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Type in 2026
- Figure 14. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Type (2021-2026)
- Figure 15. Product Picture of Balanced
- Figure 16. Product Picture of Biased
- Figure 17. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Receptor Agonist Properties in 2026
- Figure 18. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Receptor Agonist Properties (2021-2026)
- Figure 19. Product Picture of Long-acting
- Figure 20. Product Picture of Short-acting
- Figure 21. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Medicinal Efficacy in 2026
- Figure 22. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Medicinal Efficacy (2021-2026)
- Figure 23. Dual GLP-1R/GIPR Receptor Agonist Consumed in Diabetes
- Figure 24. Global Dual GLP-1R/GIPR Receptor Agonist Market: Diabetes (2021-2026)

& (K Units)

Figure 25. Dual GLP-1R/GIPR Receptor Agonist Consumed in Obesity

Figure 26. Global Dual GLP-1R/GIPR Receptor Agonist Market: Obesity (2021-2026) & (K Units)

Figure 27. Dual GLP-1R/GIPR Receptor Agonist Consumed in Others

Figure 28. Global Dual GLP-1R/GIPR Receptor Agonist Market: Others (2021-2026) & (K Units)

Figure 29. Global Dual GLP-1R/GIPR Receptor Agonist Sale Market Share by Application (2025)

Figure 30. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Application in 2026

Figure 31. Dual GLP-1R/GIPR Receptor Agonist Sales by Company in 2026 (K Units)

Figure 32. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Company in 2026

Figure 33. Dual GLP-1R/GIPR Receptor Agonist Revenue by Company in 2026 (\$ millions)

Figure 34. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Company in 2026

Figure 35. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Geographic Region (2021-2026)

Figure 36. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Geographic Region in 2026

Figure 37. Americas Dual GLP-1R/GIPR Receptor Agonist Sales 2021-2026 (K Units)

Figure 38. Americas Dual GLP-1R/GIPR Receptor Agonist Revenue 2021-2026 (\$ millions)

Figure 39. APAC Dual GLP-1R/GIPR Receptor Agonist Sales 2021-2026 (K Units)

Figure 40. APAC Dual GLP-1R/GIPR Receptor Agonist Revenue 2021-2026 (\$ millions)

Figure 41. Europe Dual GLP-1R/GIPR Receptor Agonist Sales 2021-2026 (K Units)

Figure 42. Europe Dual GLP-1R/GIPR Receptor Agonist Revenue 2021-2026 (\$ millions)

Figure 43. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales 2021-2026 (K Units)

Figure 44. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Revenue 2021-2026 (\$ millions)

Figure 45. Americas Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Country in 2026

Figure 46. Americas Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Country (2021-2026)

Figure 47. Americas Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Type

(2021-2026)

Figure 48. Americas Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Application (2021-2026)

Figure 49. United States Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 50. Canada Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 51. Mexico Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 52. Brazil Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 53. APAC Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Region in 2026

Figure 54. APAC Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Region (2021-2026)

Figure 55. APAC Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Type (2021-2026)

Figure 56. APAC Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Application (2021-2026)

Figure 57. China Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 58. Japan Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 59. South Korea Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 60. Southeast Asia Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 61. India Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 62. Australia Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 63. China Taiwan Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 64. Europe Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Country in 2026

Figure 65. Europe Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Country (2021-2026)

Figure 66. Europe Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Type (2021-2026)

Figure 67. Europe Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Application (2021-2026)

Figure 68. Germany Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 69. France Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 70. UK Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 71. Italy Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 72. Russia Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 73. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Country (2021-2026)

Figure 74. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Type (2021-2026)

Figure 75. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Market Share by Application (2021-2026)

Figure 76. Egypt Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 77. South Africa Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 78. Israel Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 79. Turkey Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 80. GCC Countries Dual GLP-1R/GIPR Receptor Agonist Revenue Growth 2021-2026 (\$ millions)

Figure 81. Manufacturing Cost Structure Analysis of Dual GLP-1R/GIPR Receptor Agonist in 2026

Figure 82. Manufacturing Process Analysis of Dual GLP-1R/GIPR Receptor Agonist

Figure 83. Industry Chain Structure of Dual GLP-1R/GIPR Receptor Agonist

Figure 84. Channels of Distribution

Figure 85. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Forecast by Region (2027-2032)

Figure 86. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share Forecast by Region (2027-2032)

Figure 87. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share Forecast by Type (2027-2032)

Figure 88. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share Forecast by Type (2027-2032)

Figure 89. Global Dual GLP-1R/GIPR Receptor Agonist Sales Market Share Forecast by Application (2027-2032)

Figure 90. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Dual GLP-1R/GIPR Receptor Agonist Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GE56925F1292EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE56925F1292EN.html>